Phase I results from the controlled phase I/II IR11330 trial assess the safety and efficacy of thermal ablation plus toripalimab, a humanized PD-1 antibody, in 46 patients (arm A: toripalimab monotherapy, n = 16; arm B: subtotal ablation + toripalimab on day 3, n = 16; arm C: ablation + toripalimab on day 14, n = 16) with advanced HCC found and an ORR of 18.8% in arm A, 37.5% in arm B, and 31.2% in arm C [247]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.